Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome

Abstract

INTRODUCTION:

Traditional cardiovascular risk factors such as central obesity, high blood pressure and insulin resistance, all constituents of metabolic syndrome, have been associated with increased levels of C-reactive protein (CRP). Therefore, this marker of low-grade inflammation may play a major role in the pathogenesis of cardiovascular diseases. In this study, data from a representative sample of urban adults was used to evaluate the association between CRP and metabolic syndrome, accounting for the type and number of its constituents.

METHODS:

Using random digit dialing, 1022 participants, aged 18–92 y, were selected. All participants completed a structured questionnaire comprising of information on social, demographic, behavioral and clinical aspects. Anthropometrics and blood pressure were recorded and a fasting blood sample collected. Metabolic syndrome was defined, according to the Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, as the presence of three or more of the following characteristics: waist circumference greater than 102 cm in men and 88 cm in women; triglyceride levels ≥150 mg/dl; high-density lipoprotein cholesterol levels <40 mg/dl in men and <50 mg/dl in women; blood pressure ≥130/85 mm Hg; and serum glucose ≥110 mg/dl. High-sensitivity CRP was assessed by immunonephelometric assay. After excluding 65 participants with CRP ≥10 mg/l, 957 subjects (599 women and 358 men) remained for analysis. Geometric means were compared after adjustment for age, sex, alcohol consumption and smoking.

RESULTS:

Higher mean levels of CRP (2.34 vs 1.36, P<0.001) were observed when metabolic syndrome was present. Also, mean CRP levels were significantly higher in the presence of central obesity (2.45 vs 1.24, P<0.001), high blood pressure (1.76 vs 1.12, P<0.001), hypertriglyceridemia (2.17 vs 1.32, P<0.001) and high fasting glucose (1.96 vs 1.46, P=0.032). We found a significant increasing trend (P<0.001) in mean levels of CRP as the number of features of metabolic syndrome increased. The major contributing features for high CRP levels were central obesity and high blood pressure.

CONCLUSIONS:

Present data show that increasing severity of metabolic syndrome is associated with increasing CRP. Additionally, we found that central obesity and high blood pressure are the most important determinants of the low-grade chronic inflammation present in metabolic syndrome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539–553.

    Article  CAS  Google Scholar 

  2. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R, Haffner S . Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–47.

    Article  CAS  Google Scholar 

  3. Ford E . The metabolic syndrome and C-reactive protein, fibrinogen, and leucocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351–358.

    Article  CAS  Google Scholar 

  4. Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets J, Drouet L, Ferrières J . Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002; 25: 1371–1377.

    Article  Google Scholar 

  5. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly D, Haffner S, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419.

    Article  CAS  Google Scholar 

  6. Han T, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S . Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016–2021.

    Article  CAS  Google Scholar 

  7. Ridker P, Buring J, Cook N, Rifai N . C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391–397.

    Article  Google Scholar 

  8. Yudkin J, Stehouwer C, Emeis J, Coppack S . C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.

    Article  CAS  Google Scholar 

  9. Hak A, Stehouer C, Bots M, Polderman K, Schalkwijk C, Westendorp I, Hofman A, Witteman JCM . Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986–1991.

    Article  CAS  Google Scholar 

  10. Fröhlich M, Imhof A, Berg G, Hutchinson W, Pepys M, Boeing H, Muche R, Brenner H, Koenig W . Association between C-reactive protein and features of the metabolic syndrome. A population-based study. Diabetes Care 2000; 23: 1835–1839.

    Article  Google Scholar 

  11. Shen B, Todaro J, Niaura R, McCaffery J, Zhang J, Spiro III A, Ward KD . Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157: 701–711.

    Article  Google Scholar 

  12. Meigs J . Insulin Resistance Syndrome? Multiple Metabolic Syndrome? A Syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908–911.

    Article  CAS  Google Scholar 

  13. Sesso H, Buring J, Rifai N, Blake G, Gaziano J, Ridker P . C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945–2951.

    Article  CAS  Google Scholar 

  14. Pearson T, Mensah G, Alexander R, Anderson J, Cannon III R, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F . Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.

    Article  Google Scholar 

  15. Ridker P . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363–369.

    Article  Google Scholar 

  16. Yeh E, Willerson J . Coming of age C-reactive protein. Using inflammation markers in cardiology. Circulation 2003; 107: 370–372.

    Article  Google Scholar 

  17. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C . Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979.

    Article  CAS  Google Scholar 

  18. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB . C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984–1992. Circulation 1999; 99: 237–242.

    Article  CAS  Google Scholar 

  19. Witherell H, Smith K, Friedman G, Ley C, Thom D, Orentreich N, Vogelman JH, Parsonnet J . C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction. Ann Epidemiol 2003; 13: 170–177.

    Article  Google Scholar 

  20. Ridker P, Glynn R, Hennekens C . C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007–2011.

    Article  CAS  Google Scholar 

  21. Ridker P, Hennekens C, Buring J, Rifai N . C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.

    Article  CAS  Google Scholar 

  22. Ridker P, Rifai N, Pfeffer M, Sacks F, Moye L, Goldman S, Flaker GC, Braunwald E, Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839–844.

    Article  CAS  Google Scholar 

  23. Lopes C . Diet and Myocardial Infarction: A Community-Based Case–Control Study. [PhD]. University of Porto: Porto; 2000.

    Google Scholar 

  24. Ramos E, Lopes C, Barros H . Investigating the effect of nonparticipation using a population-based case–control study on myocardial infarction. Ann Epidemiol 2004; 14: 437–441.

    Article  Google Scholar 

  25. Folstein M, Folstein S, Mchush P . Mini mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189–198.

    Article  CAS  Google Scholar 

  26. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ . Human blood pressure determination by sphygmomanometry. Circulation 1993; 88: 2460–2470.

    Article  CAS  Google Scholar 

  27. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

  28. Lagrand W, Visser C, Hermens W, Niessen H, Verheugt F, Wolbink G, Hack CE . C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 1999; 100: 96–102.

    Article  CAS  Google Scholar 

  29. Burke A, Tracy R, Kolodgie F, Malcom G, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R . Elevated C-reactive protein values and atherosclerosis in sudden coronary death. Association with different pathologies. Circulation 2002; 105: 2019–2023.

    Article  CAS  Google Scholar 

  30. Blake G, Ridker P . C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002; 22: 1512–1513.

    Article  Google Scholar 

  31. Yasojima K, Schwab C, McGeer EG, McGeer PL . Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039–1051.

    Article  CAS  Google Scholar 

  32. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235.

    Article  CAS  Google Scholar 

  33. Danesh J, Collins R, Appleby P, Peto R . Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta -analyses of prospective studies. JAMA 1998; 279: 1477–1482.

    Article  CAS  Google Scholar 

  34. Das U . Is obesity an inflammatory condition? Nutrition 2001; 17: 953–966.

    Article  CAS  Google Scholar 

  35. Santos A, Lopes C, Barros H . Prevalence of metabolic syndrome in the city of Porto. Rev Port Cardiol 2004; 23: 45–52.

    PubMed  Google Scholar 

  36. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P . Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002; 106: 2908–2912.

    Article  CAS  Google Scholar 

  37. Daniels SR . Cardiovascular disease risk factors and atherosclerosis in children and adolescents. Curr Atheroscler Rep 2001; 3: 479–485.

    Article  CAS  Google Scholar 

  38. Imhof A, Fröhlich M, Brenner H, Boeing H, Pepys M, Koenig W . Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 763–767.

    Article  CAS  Google Scholar 

  39. Albert M, Glynn R, Ridker P . Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003; 107: 443–447.

    Article  Google Scholar 

  40. Grundy S, Hansen B, Smith S, Cleeman J, Kahn R . Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004; 109: 551–556.

    Article  Google Scholar 

Download references

Acknowledgements

This study was funded by the Fundação para a Ciência e Tecnologia, Praxis 2/2.1/SAU/1332/95, POCTI/ESP/35767/99 and POCTI/ESP/42361/2001.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A-C Santos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santos, AC., Lopes, C., Guimarães, J. et al. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes 29, 1452–1456 (2005). https://doi.org/10.1038/sj.ijo.0803035

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803035

Keywords

This article is cited by

Search

Quick links